INTRODUCTION
The proteasome inhibitor bortezomib is approved for the treatment of multiple myeloma (MM), 1, 2 with single-agent bortezomib a standard-of-care for relapsed MM. 3, 4 Previously, intravenous (IV) injection was the standard route of bortezomib administration; 1,2 however, recently the US FDA and Health
Canada have approved addition of the subcutaneous (SC) route of administration to the prescribing information for bortezomib. 1 Benefits of SC administration include improved convenience, and, in certain patients, overcoming the issue of poor venous access.
Approval of SC administration was based upon the results of the phase 3
MMY-3021 study of SC versus IV bortezomib in 222 patients with relapsed MM following 1-3 prior lines of therapy. 5 The study demonstrated non-inferior efficacy with SC bortezomib compared with IV bortezomib in terms of the primary endpoint of overall response rate (ORR) after four cycles of singleagent therapy. 5 Additionally, comparable efficacy was seen across all secondary endpoints, while SC bortezomib appeared to be associated with an improved systemic safety profile.
5
Per protocol, the primary analysis of MMY-3021 was performed after the final patient had completed four cycles of bortezomib treatment. Consequently, median follow-up at the initial report was less than 1 year. 5 At that time, a small number of patients were ongoing on the SC arm, less than half of patients had relapsed or progressed, and overall survival (OS) data were not mature, with 27% of patients having died. Confirmation of the initial findings of comparable outcomes between SC and IV bortezomib after longer-term follow-up is thus important. Here we report the protocol-specified final analysis for survival, conducted 1-year after the last patient had been randomized. 
DESIGN AND METHODS

Patients and study design
The study design has been published previously. 5 were the thighs and abdomen, and were rotated for successive injections. The IV injection concentration was 1 mg/mL. 5 Response and progression were assessed using a validated computer algorithm applying European Group for Blood and Marrow Transplantation (EBMT) criteria. 7 Additional response categories of near-CR 8 and very good partial response (VGPR) 9 were incorporated. Adverse events (AEs) were assessed according to the National Cancer Institute's Common Terminology Criteria for AEs (NCI-CTCAE) DOI: 10.3324/haematol.2012.067793 version 3.0. After completing treatment, patients were assessed every eight weeks until disease progression and then followed up every twelve weeks for survival and subsequent therapies.
Statistical methods
The primary objective was to demonstrate non-inferiority of SC versus IV bortezomib as measured by ORR after four cycles of treatment. The noninferiority hypothesis was proven at the initial analysis (p=0.002). 5 Additional response endpoints, including best ORR, and CR/near-CR and VGPR rates, were updated at this analysis for the response-evaluable population, using central laboratory M-protein assessment. 5 Updated time-to-event endpoints
were analyzed in the intent-to-treat population using the Kaplan-Meier method. This study is registered with ClinicalTrials.gov (NCT00722566) and
EudraCT (2008-000952-28).
RESULTS AND DISCUSSION
As previously reported, 5 222 patients were randomized to SC (N=148) or IV (N=74) bortezomib. Baseline demographics and disease characteristics were generally similar between treatment arms. 5 The findings of this protocol-specified final analysis confirmed response data reported at the initial analysis. 5 Among 145 and 73 response-evaluable patients in the SC and IV arms, respectively, best ORR was 52% in each arm (n=76 and n=38, respectively), which was unchanged from the previous report Median duration of response was 9.7 months (95% CI: 8.1, 13.6) and 9.9 months (95% CI: 7.6, 12.9) for responders in the SC and IV arms, respectively.
This protocol-specified final analysis, after prolonged median follow-up, also confirmed that long-term outcomes were comparable following SC or IV bortezomib. At data cut-off, 129 of 222 patients (58%) had relapsed or progressed. There remained no significant difference in time to progression (TTP; Figure 1A ) or progression-free survival (PFS; Figure 1B ) between arms (censoring for subsequent therapy), and data were numerically similar.
Median TTP was 9.7 months (95% CI: 8.5, 11.7) and 9.6 months (95% CI: Table 1 ; subsequent melphalan and prednisolone appeared more common (>5% rate difference) following SC versus IV bortezomib, and 7 [9%], respectively). There was no significant difference in OS ( Figure   1C ); median OS was 28.7 months (95% CI: 23.2, not estimable) and not estimable (95% CI: 21.5, not estimable) in the SC and IV arms, respectively.
One-year survival rates were 76.4% (95% CI: 68.5, 82.5) and 78.0% (95% CI:
66.7, 85.9), respectively (p=0.788). In sub-group analyses restricted to patients enrolled in first relapse, TTP, PFS, and OS remained similar between arms (data not shown). It should be noted that, overall, only 55% of patients had received subsequent therapy and only approximately one-third of patients had died at this final analysis. Nevertheless, these data provide important confirmation of an equivalent clinical benefit from bortezomib whether administered by the SC or IV route.
Compared with the previous report 5 there were only minor updates to the safety profile of SC bortezomib; data for IV bortezomib were unchanged. By
MedDRA system organ class, one additional SC patient had a grade ≥3
gastrointestinal event (grade ≥3 diarrhea), and one additional patient had an AE in the metabolism and nutrition disorders and nervous system disorders
classes. An additional SC patient experienced a grade ≥ 3 reduction in absolute neutrophil count, based on hematology laboratory data.
PN rates were unchanged from the previous report, remaining significantly lower in the SC versus the IV arm (all-grade: 38% vs. 53%, p=0.044; grade ≥2: 24% vs. 41%, p=0.012; grade ≥ 3: 6% vs. 16%, p=0.026). Per the initial dataset, the cumulative dose of SC or IV bortezomib to the first onset of any grade, grade ≥2, and grade ≥3 PN is shown in Figure 2 . These data suggest that SC versus IV administration of bortezomib results in a lower rate of susceptibility to PN rather than any differences in timing of PN onset.
The rates of resolution or improvement of PN events in both arms were high, and were increased compared with the initial report. 5 In the SC arm, 58 of 78 (74%) PN events had resolved or improved in a median of 2.5 months (range, These higher rates of resolution or improvement compared with the initial report, 5 coupled with the similar median time to resolution or improvement, demonstrate that PN continues to resolve with prolonged follow-up and is reversible in the majority of patients. These data reflect previous reports of bortezomib-associated PN in both previously untreated 10 and relapsed MM.
11
In conclusion, SC administration of bortezomib appears an equally effective treatment option to IV bortezomib, with some notable improvements in the systemic safety profile. These findings may be reflected when using SC bortezomib in the first-line setting in combination regimens that have demonstrated substantial activity using IV bortezomib. [12] [13] [14] [15] [16] [17] [18] Importantly, SC bortezomib might be used instead of IV bortezomib in highly active combinations employing weekly bortezomib dosing 12, 16, 17 as a means of further reducing the rate of PN. 
